Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo, with top-line results expected in mid-2025Phase 1a SAD/MAD trial of VYN202…
Applauds first FDA approval of non-injection-based epinephrine deviceReiterates expected timing for filing of New Drug Application (NDA) for Anaphylm™ (epinephrine)…
Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of…
– Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 – – Registrational RECOVER-2 trial in schizophrenia expected to…
- Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH’s distribution footprint…
MARLBOROUGH, Mass., Aug. 13, 2024 /PRNewswire/ -- Quantiphi, an award-winning AI-first digital engineering company today announced it has acquired a…
HALIFAX, NS / ACCESSWIRE / August 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces it will conduct full clinical…
~ Second Quarter 2024 Revenue Increased 21% Year-Over-Year ~~ Surgical Procedures Increased 7% Year-Over-Year in the Second Quarter 2024 ~~…
Leading Victorian healthcare network integrates oncology and EHR solutions to deliver more informed care across its locations AUSTIN, Texas and VICTORIA, Australia,…
Clario integrates Mobilise-D's algorithms into Clario's Opal®️ wearable sensor system to enable real-world mobility assessments that generate accurate and reliable…